Galapagos News - GXE

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors Supportive...

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 Preliminary results from...

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022 Guiding principles for a sustainable future: Invest in...

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results Clear path forward for accelerated growth...

Galapagos to host its R&D Update 2022 in New York on 4 November 2022

Galapagos to host its R&D Update 2022 in New York on 4 November 2022 Mechelen, Belgium; 17 October 2022, 07.30 CET; - Galapagos NV...

Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022...

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies...

Galapagos increases share capital through subscription right exercises

Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 27 September 2022, 22.01 CET; regulated information...

Galapagos receives transparency notification from FMR LLC

Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 29 August 2022, 22.01 CET; regulated information – Galapagos NV...

Galapagos to present at upcoming investor conferences

Galapagos to present at upcoming investor conferences Mechelen, Belgium; 24 August 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ:...

Galapagos receives transparency notification from FMR LLC

Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 18 August 2022, 22.01 CET; regulated information – Galapagos NV...

Galapagos receives transparency notification from FMR LLC

Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 8 August 2022, 22.01 CET; regulated information – Galapagos NV...

First key steps in pipeline rebuild and strong commercial progress in H1 2022

First key steps in pipeline rebuild and strong commercial progress in H1 2022 First half-year 2022 financial results: Jyseleca® net sales...

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies Potential for paradigm shift in CAR-T...

Galapagos increases share capital through subscription right exercises

Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information –...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Galapagos (GXE)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GXE News

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos to host its R&D Update 2022 in New York on 4 November 2022

Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

Galapagos increases share capital through subscription right exercises

Galapagos receives transparency notification from FMR LLC

Galapagos to present at upcoming investor conferences

Galapagos receives transparency notification from FMR LLC

Galapagos receives transparency notification from FMR LLC

First key steps in pipeline rebuild and strong commercial progress in H1 2022

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

Galapagos increases share capital through subscription right exercises

GXE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Galapagos (GXE) News

Galapagos (GXE)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GXE News

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos to host its R&D Update 2022 in New York on 4 November 2022

Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

Galapagos increases share capital through subscription right exercises

Galapagos receives transparency notification from FMR LLC

Galapagos to present at upcoming investor conferences

Galapagos receives transparency notification from FMR LLC

Galapagos receives transparency notification from FMR LLC

First key steps in pipeline rebuild and strong commercial progress in H1 2022

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

Galapagos increases share capital through subscription right exercises

GXE Discussion

Your Recent History